Tirzepatide is a dual GIP and GLP-1 receptor agonist, offering a broader metabolic approach by targeting two key hormone pathways involved in appetite and glucose regulation.
It supports:
Appetite reduction
Enhanced metabolic efficiency
Improved insulin sensitivity
How it works:By activating both GIP and GLP-1 receptors, Tirzepatide influences hunger signalling, energy utilisation, and blood sugar balance more comprehensively than single-pathway therapies.
Commonly used in clinical settings for:
Advanced weight management strategies
Metabolic optimisation
Blood sugar regulation support
Use is typically supervised by a qualified medical professional.
Tirzepatide
Metabolic Peptide Therapy Overview
Our metabolic peptide offerings include Semaglutide, Tirzepatide, and Retatrutide (RETA) — advanced therapies used under medical supervision to support appetite regulation, metabolic balance, and blood sugar control.
Semaglutide
A GLP-1 receptor agonist that supports appetite control by promoting satiety and reducing hunger signals. Commonly used as part of structured weight-management and metabolic health programs.
Tirzepatide
A dual GIP and GLP-1 receptor agonist that targets two key metabolic pathways, offering broader support for appetite regulation, insulin sensitivity, and overall metabolic efficiency.
Retatrutide (RETA)
A next-generation triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors, designed to support comprehensive metabolic processes and energy regulation in advanced clinical settings.
Important Notice!
These therapies are prescribed and used only under the supervision of qualified healthcare professionals. Information provided is for educational purposes only and does not replace medical advice.
